Table 7

Sensitivity analyses of NashTest for the diagnosis of Borderline Nash or Nash versus No Nash [Area under the ROC curves (AUROCs)], according to group, ALT values, alcohol consumption, quality of biopsy, inclusion of patients without steatosis, and exclusion of high risk of biomarkers failures.

Characteristic of patients

n

NashTest AUROC

Lower 95%

Upper 95%

Prevalence Borderline or NASH

Significance


All 257 patients

257

0.78

0.72

0.84

0.38

Stratified according to Group*

Training Group

160

0.77

0.68

0.84

0.36

0.34

Validation Group

97

0.83

0.67

0.90

0.42

Stratified according to ALT value*

ALT< 50IU/L

92

0.74

0.62

0.82

0.50

0.24

ALT>= 50 IU/L

165

0.81

0.73

0.87

0.32

Stratified according to Alcohol consumption*

None

95

0.78

0.67

0.86

0.37

0.83 and 0.20

< 30 g for men and < 20 g for female

150

0.77

0.66

0.84

0.39

0.83 and 0.19

>= 30 g for men or >= 20 g for female

12

1.00

0.35

1.00

0.33

0.20 and 0.19

Stratified according to Quality of biopsy*

< 25 mm

194

0.78

0.71

0.84

0.39

0.98

>= 25 mm

63

0.78

0.63

0.88

0.37

Fragmented

148

0.77

0.68

0.84

0.36

0.46

Not Fragmented

109

0.81

0.71

0.88

0.40

Patients included or excluded

Patients without steatosis included**

272

0.79

0.72

0.84

0.39

0.83

High risk of NashTest failures excluded**

Gilbert excluded

244

0.78

0.71

0.83

0.39

0.97

Acute Inflammation excluded

254

0.78

0.72

0.84

0.38

0.98


* Comparison between stratified groups

** Comparison with all 257 patients

Poynard et al. BMC Gastroenterology 2006 6:34   doi:10.1186/1471-230X-6-34

Open Data